Abstract:Objectives To explore the clinical significance of tyrosine kinase receptor RON mRNA expression and it's splicing variant in bladder tumors. Methods Sixty-three cases of transitional cell carcinoma of the bladder (TCCB), including 30 cases of pathological grade I , 15 cases of pathological grade Ⅱ and 18 cases of pathological grade Ⅲ (44 cases of clinical stage Tis + T1, 15 cases of T2 + T3 +T4), 7 inverted papilloma of the bladder ( IPB), 9 cases of papillary urothelial neoplasm of low malignant potential (PUNLMP) and 12 cases of normalbladder mucosa RT-PCR was employed with the internal standard (GAPDHmRNA) to detect the expression of RON mRNA. PCR and direct sequencing was then utilized to identify the potential RON mRNA splicing variants. Finally, the variants' positive rates of expression were analyzed among the different tissues, diverse TCCB pathological grades and clinical stages. Results The expression levels of RON mRNA/GAPDH mRNA among TCCB, IPB, PUNLMP and normal control were 4. 9 × 10-3 ( 1. 8 × 10-3-1.0 × 10-2 ), 3. 8 × 10-3 (2. 4 × 10-3-1.7 × 10-2 ), 4. 9 ×10 -3 ( 1.7 × 10 -3-1.1 × 10 -2 ) and 1.0 × 10-3 (4. 5 × 10-4-2. 8 × 10-3 ) respectively. The difference had a statistical significance (x2K-W = 17. 278 ,P ＜0. 05 ). The expression levels among pathological grade I, Ⅱ and Ⅲ were 3.7 × 10-3( 1.3 × 10-3-7.5 × 10-3) , 4. 9 × 10-3(1.9 × 10-3-1.1 × 10-2) and 8.9 × 10-3(2. 7 ×10 -3-8.0 × 10 -2 ) respectively. The erpression levels among the clinical stage Tis + T1 and T2 + T3 + T4were 3.5 × 10-3 ( 1.2 × 10 -3-7. 7 × 10-3 ) and 9. 7 × 10 -3 ( 2. 9 × 10-3-5. 3 × 10-2 ). The differences between expression levels were of statistical significance among the different pathological grades ( x2k-W =7. 341, P ＜0. 05 ) and clinical stages ( Z = - 2. 306, P ＜ 0. 05 ). The positive rates of exon 11deletion(E11△) in TCCB, IPB and PUNLMP were 71％ (45/63), 57％ (4/7) and 67％ (6/9) respectively, andthe total positive rate in bladder tumor tissues was 70％. Meanwhile, expression of the novel RON variant wesnot detected in the normalbladder mucosa. The positive expression rate of E1 1△ has no significant correlationamong the different clinical pathological tissues (x2 = 0. 620, P ＞ 0. 05 ). There was no statistical significancein expression positive rate between different pathological grades ( Z =0. 221, P ＞0. 05 ) and clinical stages( Z = 0. 538, P ＞ 0. 05) as well. A novel RON splice variant, deletion of RON exon 11 3 476 - 3 539 ( E3476 -3539△) was fond in the pathological tissue. The positive expression rates of E3 476 -3 539 in TCCB,IPB and PUNLMP were 57％ (36/63), 43％ (3/7) and 56％ (5/9) respectively, and the total positive expression rate was 56％ (44/79). The positive rates of E3 476 -3 539△ in pathological grade I , Ⅱ and Ⅲ were 40％ ( 12/30), 67％ (10/15) and 78％ (14/18), and it's positive rates in clinical stage Tis +T1and T2 +T3 + T4 were 48％ (21/44) and 80％ (12/15). The differences in each group had significantly statistical significance ( Z = 7. 285, 5. 041, P ＜ 0. 05 ) . However, the positive rates amongdifferent pathological tissues had no significance (x2 = 0. 517, P ＞ 0. 05 ). Conclusions The expression level of RON mRNA is significantly associated with histological grading and clinical stage. RON may play an important role in the progression ofTCCB. Compared with the normal control, the increased RON variant expression may contribute to the carcinogenesis of the bladder tumor.

Association between clinical characteristics and expression abundance of RTKN gene in human bladder carcinoma tissues from Chinese patients

Significance of Tyrosine Kinase Receptor Gene and Its Variant Expressions in Bladder Tumor Tissues

The relationship of expression of p53,p21,Ki-67 and VEGF and bladder cancer stage,grade and prognosis

RTKN2 is Associated with Unfavorable Prognosis and Promotes Progression in Non-Small-Cell Lung Cancer

Pan-cancer Analysis and KNSTRN As a Potential Prognosis Biomarker

Selection of Reference Genes for Gene Expression Studies in Human Bladder Cancer Using SYBR-Green Quantitative Polymerase Chain Reaction.

The Association of Rs710886 in Lncrna PCAT1 with Bladder Cancer Risk in a Chinese Population.

Heterogeneous Nuclear Ribonucleoprotein K is Associated with Poor Prognosis and Regulates Proliferation and Apoptosis in Bladder Cancer

Gene expression profile and enrichment pathways in different stages of bladder cancer

Expression and Clinical Significance of Tumor Associated Antigen MUC1 and Its Isoform MUC1/Y mRNA in Bladder Cancer

Clinical significance of KRT7 in bladder cancer prognosis

Comprehensive analysis of Transcription Factors identified novel prognostic biomarker in human bladder cancer

Clinicopathological and Prognostic Impact of Somatic Mutations in Chinese Patients with Clear Cell Renal Cell Carcinoma

Downregulated KLK13 expression in bladder cancer highlights tumor aggressiveness and unfavorable patients’ prognosis

Long Noncoding RNA Expression Signatures of Bladder Cancer Revealed by Microarray

Oncogene Mir-187-5p is Associated with Cellular Proliferation, Migration, Invasion, Apoptosis and an Increased Risk of Recurrence in Bladder Cancer.

Abstract B05: Basic Research and Translational Medicine of Bladder Cancer in China

Gene expression profile changes in human bladder superficial transitional cell carcinoma

Exploration of prognostic biomarkers and therapeutic targets in the microenvironment of bladder cancer based on CXC chemokines

Identification of key candidate genes and biological pathways in bladder cancer

Long Non-Coding RNA Expression Profiles for the Characterization of Different Bladder Cancer Grade